心血管改造:关键机制和临床影响,将肉症和心力衰竭联系在一起
Jinghong Yang1,2, Xinyu Zhang3, Jun Zhong1
1Department of Orthopedics, Rongchang District People's Hospital, Chongqing, China.
Frontiers in medicine
|March 2, 2026
概括
麻症和心力衰竭共享诸如炎症和氧化应激之类的共同途径,心血管重塑加剧了这两种情况. 针对这些联系的新疗法可能会改善患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 老年学是一门学科.
- 生理学 生理学 生理学
背景情况:
- 石症和心力衰竭 (HF) 呈现出双向关系.
- 心血管改造是将这些疾病联系起来的关键媒介.
- 共同的病理生理机制包括慢性炎症,氧化应激和胰岛素抵抗.
研究的目的:
- 审查缩症和心力衰竭的相互联系.
- 检查共享的病理生理机制和心血管改造的作用.
- 讨论这些相关疾病的新型治疗点.
主要方法:
- 综合临床和实验证据的文献综述.
- 分析萨尔科佩尼亚和HF常见的病理生理路径.
- 识别潜在的治疗策略.
主要成果:
- 心血管改造加剧了萨尔科佩尼亚的肌肉损失和高血压心脏功能障碍.
- 炎症,氧化应激和胰岛素抵抗等共享机制至关重要.
- 新的治疗目标正在出现,以破坏这些常见的途径.
结论:
- 建议制定一个统一的框架,以了解肉病和高频率的联系.
- 心血管改造在这两种疾病的进展中起着重要作用.
- 针对共享途径提供了改善治疗策略和患者结果的潜力.
相关概念视频
Pathophysiology of Heart Failure
4.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure II: Pathophysiology
1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure I: Introduction
1.1K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Cardiomyopathy V: Interprofessional Care
551
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
551
Cardiomyopathy III: Hypertrophic Cardiomyopathy
578
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
578


